癌症患者偶发肺栓塞的治疗与长期临床结局:一项国际前瞻性队列研究
该国际前瞻性观察性队列研究纳入695例活动性癌症合并近期偶发肺栓塞患者,随访12个月。97%患者启动抗凝治疗,其中89%使用低分子量肝素。12个月静脉血栓栓塞复发累积发生率6.0%,大出血5.7%,全因死亡43%。亚段肺栓塞复发率6.4%,与更近端肺栓塞的6.0%相比无显著差异(亚分布风险比1.1,95%CI 0.37-2.9,P=0.93)。
要点
- 癌症偶发肺栓塞患者抗凝治疗下12个月静脉血栓栓塞复发累积发生率为6.0%。
- 亚段肺栓塞与更近端肺栓塞的12个月复发风险无显著差异(亚分布风险比1.1)。
- 12个月全因死亡累积发生率为43%,大出血为5.7%。
核心结论
- 癌症偶发肺栓塞患者尽管接受抗凝治疗,静脉血栓栓塞复发风险仍显著。
- 亚段肺栓塞患者的静脉血栓栓塞复发风险似乎与更近端血栓患者相当。
研究设计与样本
- 国际前瞻性观察性队列研究,于2012年10月22日至2017年12月31日开展。
- 纳入未经选择的活动性癌症合并近期偶发肺栓塞成人患者,共695例。
- 随访12个月,结局事件包括静脉血栓栓塞复发、大出血和全因死亡,均经中心裁定。
主要发现
- 患者平均年龄66岁,男性占58%;最常见癌症类型为结直肠癌(21%)和肺癌(15%)。
- 675例(97%)启动抗凝治疗,其中600例(89%)使用低分子量肝素。
- 12个月静脉血栓栓塞复发累积发生率为6.0%(95%CI 4.4%-8.1%),共41例。
- 12个月大出血累积发生率为5.7%(95%CI 4.1%-7.7%),共39例;全因死亡累积发生率为43%(95%CI 39%-46%),共283例。
- 亚段肺栓塞患者12个月静脉血栓栓塞复发率为6.4%,更近端肺栓塞患者为6.0%(亚分布风险比1.1,95%CI 0.37-2.9,P=0.93)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pulmonary embolism is incidentally diagnosed in up to 5% of patients with cancer on routine imaging scans. The clinical relevance and optimal therapy for incidental pulmonary embolism, particularly distal clots, is unclear. The aim of the current study was to assess current treatment strategies and the long-term clinical outcomes of incidentally detected pulmonary embolism in patients with cancer. PATIENTS AND METHODS: We conducted an international, prospective, observational cohort study between October 22, 2012, and December 31, 2017. Unselected adults with active cancer and a recent diagnosis of incidental pulmonary embolism were eligible. Outcomes were recurrent venous thromboembolism, major bleeding, and all-cause mortality during 12 months of follow-up. Outcome events were centrally adjudicated. RESULTS: A total of 695 patients were included. Mean age was 66 years and 58% of patients were male. Most frequent cancer types were colorectal (21%) and lung cancer (15%). Anticoagulant therapy was initiated in 675 patients (97%), of whom 600 (89%) were treated with low-molecular-weight heparin. Recurrent venous thromboembolism occurred in 41 patients (12-month cumulative incidence, 6.0%; 95% CI, 4.4% to 8.1%), major bleeding in 39 patients (12-month cumulative incidence, 5.7%; 95% CI, 4.1% to 7.7%), and 283 patients died (12-month cumulative incidence, 43%; 95% CI, 39% to 46%). The 12-month incidence of recurrent venous thromboembolism was 6.4% in those with subsegmental pulmonary embolism compared with 6.0% in those with more proximal pulmonary embolism (subdistribution hazard ratio, 1.1; 95% CI, 0.37 to 2.9; P = .93). CONCLUSION: In patients with cancer with incidental pulmonary embolism, risk of recurrent venous thromboembolism is significant despite anticoagulant treatment. Patients with subsegmental pulmonary embolism seemed to have a risk of recurrent venous thromboembolism comparable to that of patients with more proximal clots.
引用
- Kraaijpoel N, Bleker SM, Meyer G, et al. Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study. J Clin Oncol. 2019. PMID: 31116676. doi:10.1200/JCO.18.01977
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。